.95 I.1.3.2.2 Prise en charge des complications liées à l'évolution de la maladie97 ? Troubles du sommeil, Troubles tensionnels, vol.100, p.101 ,
.105 I.2.1 Traitement chirurgical, .108 I.2.2.2 L'ergothérapie ,
111 II.1 La stimulation magnétique transcrânienne111 II.2 La thérapie cellulaire111 II.2.1 Les greffes de cellules humaines foetales, ., p.111 ,
112 II.4 Inhibition enzymatique : inhibition de la sirtuine 2, p.113 ,
114 II.1 La population115 II.2 Le traitement, 117 II.2.2 Aspect général, p.135 ,
136 II.3.2.1 Les fluctuations, ., p.145 ,
La maladie de Parkinson : critères diagnostiques et thérapeutiques . Texte court, Rev Prat, vol.14, issue.497, pp.832-838, 2000. ,
An essay on the shaking palsy, pp.1817-66 ,
La maladie de Parkinson et ses traitements, Impact Pharmacien, vol.38, pp.32-37, 1999. ,
Prendre en charge toutes les dimensions de la maladie ,
Epidémiologie et symptômes inauguraux, Le Quotidien du médecin, pp.8025-8035, 2006. ,
Paris : Larousse, p.32, 1219. ,
Bases neurophysiologiques du mouvement.-1e ed, 296p.-(Collection sciences et pratiques du sport), 2002. ,
Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex, Annual Review of Neuroscience, vol.9, issue.1, pp.357-381, 1986. ,
DOI : 10.1146/annurev.ne.09.030186.002041
Primate models of movements disorders of basal ganglia origin., Trends ,
Motricité et grandes fonctions du système nerveux central, Paris : Dunod, vol.256, issue.2, 2000. ,
Basal ganglia motor control. III. Pallidal ablation: normal reaction time, muscle cocontraction, and slow movement, Journal of Neurophysiology, vol.65, issue.2, pp.330-351, 1991. ,
DOI : 10.1152/jn.1991.65.2.330
Neurotransmitters and neuromodulators in the basal ganglia. Trends ,
Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis, J Neurosci, vol.11, pp.1016-1031, 1991. ,
The neostriatal mosaic : multiple levels of compartmental organization ,
Flammarion, Médecine-Sciences, 1985. ,
La maladie de Parkinson et son traitement. 2 e éd ,
Maladie de Parkinson. 2 e éd, Rueil Malmaison : Doin, p.209, 2006. ,
La sécrétion et l'inactivation périphérique des catécholamines ,
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease, Brain Research, vol.275, issue.2, pp.321-328, 1983. ,
DOI : 10.1016/0006-8993(83)90993-9
Maladie de Parkinson : état des connaissances en 1999, Thèse de pharmacie, 1999. ,
Maladie de Parkinson, traitements et stratégies ,
Certitudes et controverses pharmacothérapeutiques (première partie), Pharmactuel, vol.33, issue.2, pp.36-46, 2000. ,
Prise en charge des troubles psychiques dans la Maladie de Parkinson ,
Parkinsonism: onset, progression, and mortality, Neurology, vol.17, issue.5, pp.427-442, 1967. ,
DOI : 10.1212/WNL.17.5.427
URL : http://www.neurology.org/content/17/5/427.full.pdf
Les stratégies du traitement antiparkinsonien, Rev Prat, vol.55, issue.7, pp.723-731, 2005. ,
The spectrum of levodopa-related fluctuations in Parkinson's disease, Neurology, vol.43, issue.8 ,
DOI : 10.1212/WNL.43.8.1459
Parkinson's disease The clinical use of drugs, 6 e ed, pp.1-16, 1995. ,
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table, Movement Disorders, vol.24, issue.11 ,
DOI : 10.1017/S0317167100000068
In : Guide pratique des médicaments ,
Les médicaments antiparkinsoniens : bilan et nouvelles perspectives pharmacologiques, Médecine et hygiène, pp.1852-1860, 1990. ,
An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines, Neurology, vol.50, issue.Issue 3, Supplement 3, pp.1-57, 1998. ,
DOI : 10.1212/WNL.50.3_Suppl_3.S1
Clinical Pharmacology of Dopamine Agonists in Parkinson??s Disease, Drugs & Aging, vol.13, issue.5, pp.381-390, 1998. ,
DOI : 10.2165/00002512-199813050-00004
New Pharmacotherapy for Parkinson's Disease, Annals of Pharmacotherapy, vol.44, issue.10, pp.31-1205, 1997. ,
DOI : 10.1212/WNL.44.1.77
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study, Movement Disorders, vol.18, issue.4, pp.418-425, 2003. ,
DOI : 10.1002/mds.10359
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa, New England Journal of Medicine, vol.342, issue.20 ,
DOI : 10.1056/NEJM200005183422004
SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS, The Lancet, vol.331, issue.8582, pp.403-406, 1988. ,
DOI : 10.1016/S0140-6736(88)91193-2
Troubles moteurs tardifs ,
Continuous subcutaneous apomorphine infusion : an effective and cognitive well tolerated solution for untreatable motor fluctuations in patients with Parkinson's disease. Move disord, p.79, 2005. ,
La maladie de Parkinson, aspects cliniques, physiopathologiques, étiologiques et thérapeutiques, Thèse de pharmacie, 1994. ,
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry, BMJ, vol.316, issue.7139, pp.316-1191, 1998. ,
DOI : 10.1136/bmj.316.7139.1191
Sélégiline, avec 6 ans de recul : trop de risque dans la maladie de Parkinson, Revue Prescrire, issue.227, pp.22-251, 2002. ,
Selegiline as initial treatment in de novo parkinsonian patients, Neurology, vol.42, issue.2, pp.339-343, 1992. ,
DOI : 10.1212/WNL.42.2.339
Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease, Neurology, vol.39, issue.8, pp.1109-1111, 1989. ,
DOI : 10.1212/WNL.39.8.1109
Rasagiline for motor complications in Parkinson's disease. The Lancet, pp.914-916, 2005. ,
Les traitements de la maladie de Parkinson, un demi siècle de progrès. A.I.M, pp.10-13, 2007. ,
Catéchol-O-méthyltransferase inhibition and the traitment of Parkinson's disease ,
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice, Methods and Findings in Experimental and Clinical Pharmacology, vol.24, issue.1, pp.23-32, 2002. ,
DOI : 10.1358/mf.2002.24.1.677124
Tolcapone inhibits both peripheral and central catechol-O-methyl transferase (COMT), Neurology, pp.45-252, 1995. ,
Amantadine in the Treatment of Parkinson's Disease, JAMA: The Journal of the American Medical Association, vol.208, issue.7, pp.1168-1170, 1969. ,
DOI : 10.1001/jama.1969.03160070046011
A five-year study of the incience of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa, N England J Med, issue.20, pp.342-1484, 2000. ,
Stratégie médicamenteuse initiale, pp.63-80, 1998. ,
Le médecin généraliste, p.2375, 2006. ,
Troubles associés dans la Maladie de Parkinson, Rev prat, vol.55, pp.744-746, 2005. ,
Quelles sont les indications chirurgicales dans la Maladie de Parkinson ? Le concours médical, pp.119-157, 1997. ,
Les indications dans la Maladie de Parkinson. La stimulation cérébrale profonde ,
apport de la kinésithérapie dans la prise en charge globale des patients atteints de la Maladie de Parkinson, pp.19-21, 2006. ,
Les traitements de la maladie de Parkinson, un demi siècle de progrès, A.I.M, vol.126, pp.10-13, 2007. ,
Une thérapie cellulaire prometteuse dans le Parkinson. Le quotidien du médecin, 2008. ,
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, The Lancet, vol.369, issue.9579, pp.369-2097, 2007. ,
DOI : 10.1016/S0140-6736(07)60982-9
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease, Science, vol.5837, pp.317-516, 2007. ,
Neurosciences médicales. Les bases neuroanatomiques et neurophysiologiques.-1 e ed, pp.379-407, 2002. ,
The parkinson study Group "effect of Deprenyl on the progression of disability in early Parkinson's disease, N Engl J Med, issue.20, pp.321-1364, 1989. ,
79] Modèles animaux de la Maladie de Parkinson : http://psychologie.u-strasbg.fr/documentation/RGalani/TCC_modani_3.pdf [80] Rapport européen public d'évaluation (EPAR). DATSCAN. Résumé de l'Epar à l'intention du public, 2007. ,
Guide-affection de longue durée : syndromes parkinsoniens dégénératifs ou secondaires non réversibles, 2007. ,
Médicaments et produits de santé Duodopa® : http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions, p.102539 ,